Last reviewed · How we verify
NCT04877899
Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol
trial testing EchoGo in Cardiotoxicity in 250 participants. Status unknown.
31 March 2021
Quick facts
| Lead sponsor | Ultromics Ltd |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 8 October 2020 |
| Primary completion | 31 March 2021 |
| Estimated completion | 30 November 2021 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- EchoGo
Conditions studied
- Cardiotoxicity — all drugs for Cardiotoxicity →
- Cancer — all drugs for Cancer →
Sponsor
Ultromics Ltd
Who can join
18 and older, any sex, with Cardiotoxicity or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to compare conventionally acquired Left Ventricle Ejection Fraction (LVEF) and Global Longitudinal Strain (GLS) data to Artificial Intelligence (AI) driven automated processing of 2 dimensional contrast and 2 dimensional non-contrast resting transthoracic echocardiograms for application in the assessment of patients undergoing chemotherapy with cardiotoxic drugs. This is a single-centre retrospective study which utilizes echocardiographic DICOM image and meta-data datasets received from a Canadian site. Data processed using the AI driven automated processing will be compared to conventionally acquired LVEF and GLS measurements and results will be analysed to determine accuracy and precision.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04877899
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of EchoGo
Trials testing the same drug.
- NCT05028179 — PROTEUS: Evaluating the Use of Artificial Intelligence to Support Stress Echocardiography Testing for Heart Disease · NA · unknown
Other recruiting trials for Cardiotoxicity
Currently open trials in the same condition.
- NCT07442578 — Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial · NA · active not recruiting
- NCT06778122 — In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors · NA · recruiting
- NCT07382141 — Early Identification of Cardivascular Damage Induced by Chemotherapy and Antineoplastic Treatments in Pediatric Age · NA · recruiting
- NCT06595147 — Breast cancEr, FITness and ExeRcise for Heart Health: The BE-FITTER Study · NA · recruiting
- NCT06270667 — Effects of Exercise Training in Survivors of Lymphoma · NA · recruiting
Other Ultromics Ltd trials
Trials by the same sponsor.
- NCT05028179 — PROTEUS: Evaluating the Use of Artificial Intelligence to Support Stress Echocardiography Testing for Heart Disease · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04877899 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ultromics Ltd
- Last refreshed: 5 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04877899.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing